Inclusion Criteria
- Documented diagnosis of multiple Mmyeloma (MM) as per International Myeloma Working
Group (IMWG) criteria.
- Received at least 4 classes of MM treatment [including immunomodulatory drug (IMiD),
proteasome inhibitor (PI), anti CD38 mAb, and anti-B cell maturation antigen (BCMA)
therapy], and at least 3 prior lines of therapy (LOT).
- Documented disease progression during or after their last anti-myeloma regimen as per
IMWG.
- Participants must have measurable disease during screening.
- Have measurable disease during screening.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion Criteria
- Active or history of central nervous system involvement with MM.
- Active systemic fungal, bacterial, viral, or other infection despite appropriate
anti-infective treatment at the time of leukapheresis.
- Received any prior therapy directed at G protein-coupled receptor class C, group 5,
member D (GPRC5D) or has received other prior treatment for MM without the required
washout prior to leukapheresis.
- Other protocol-defined Inclusion/Exclusion criteria apply.
